Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: Results from a randomized study

BJU International

Volumn 105, Issue 8, 2010, Pages 1126-1135

  Mattiasson, Anders ^d   Masala, Alberto ^a   Morton, Richard ^b   Bolodeoku, John ^c  

^a UOC di Urologia   (Italy)

^b Astellas Pharma Global Development   (Netherlands)

^c ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bladder training; Incontinence; Overactive bladder; Solifenacin; Urgency

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; AGED; ARTICLE; BLADDER TRAINING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MULTICENTER STUDY; OPEN STUDY; OVERACTIVE BLADDER; PARALLEL DESIGN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; PYELONEPHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; QUINUCLIDINES; SINGLE-BLIND METHOD; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 77950233050     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08910.x     Document Type: Article

References (19)

1. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 1315
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 766
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 336
4. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 178
5. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006 25 : 293 294
6. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000 6 : S574 9
7. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 340
8. Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006 4): CD003193
9. Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006 60 : 959 966
10. Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 48 : 464 470
11. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172 : 1919 1924
12. Cardozo L, Heßdörfer E, Milani R et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008 102 : 1120 1127
13. Karram MM, Toglia MR, Serels SR et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009 73 : 14 18
14. Chancellor MB, Zinner N, Whitmore K et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther 2008 30 : 1766 1781
15. Zinner N, Kobashi K, Andoh M, Smith N. Solifenacin reduces overactive bladder symptoms and improves health-related quality of life in patients previously receiving tolterodine. Urology 2006 68 (Suppl. 5A 72, Abstract MP-04.12
16. Garely AD, Kaufman JM, Sand PK et al. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial. Clin Ther 2006 28 : 1935 1946
17. Bo K, Berghmans LCM. Nonpharmacologic treatments for overactive bladder - pelvic floor exercises. Urology 2000 55 (Suppl. 5A 7 11
18. Mattiasson A, Blaakaer J, Hoye K, Wein AJ. Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003 91 : 54 60
19. Song C, Park JT, Heo KO, Lee KS, Choo M-S. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 2006 21 : 1060 1063